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Dr Klein‟s assertions about the origins of registers on drug-related death are inaccurate, probably due 
to misunderstanding some of the fundamental epidemiological indicators of drug misuse, including 
mortality. Whilst it is true that there were many deaths involving the misuse of opium, typically as 
laudanum, in the nineteenth century, the need for civil registration of deaths in the UK introduced in 
1864 was recognition of the need to monitor mortality due to fatal epidemic outbreaks of diseases 
such as typhoid, cholera, dysentery and smallpox. The UK was the first nation to commence 
recording drug-related deaths per se with the setting up of the Home Office Addicts Index in the 
1920s, and the first statistics from this source were published by the League of Nations in the early 
1930s. Publication of statistics relating to the death of these addicts continued until 1997 (Corkery 
1997). The national programme on Substance Abuse Deaths (np-SAD) was set up in 1997, in part, to 
continue to actively monitor deaths of addicts and deaths related to drug misuse as well as to provide 
a centre of expertise on epidemiology relating to this phenomenon.  
 
There is a misrepresentation of some of the information in this commentary. The case criteria 
established by np-SAD in 1997 have not changed, neither have the Programme‟s objectives or raison 
d’être (Ghodse et al, 2010). There has been no „mission creep‟ as Klein describes in respect of the 
Programme. Within the scientific community as a whole, especially in Europe, there has been a wider 
recognition of the role which the abuse of psychoactive substances has in causing morbidity and 
premature mortality. The Programme actively participates in these surveillance and research 
activities. 
 
The reason for writing this paper about „khat-related‟ deaths is to provoke a discussion about the 
nature of the links between the use of a psychoactive substance and mortality in all its shapes and 
forms. This is not an attempt to increase the need for special mortality registers by widening case 
definitions, but a vehicle to demonstrate the broad spectrum of associations, including causality, 
between activities related to the use of khat and deaths. This paper uses concrete examples reported 
to np-SAD to illustrate some of the consequences of khat consumption, as has been done in previous 
papers dealing with other substances (Schifano et al, 2003; Oyefeso et al, 2006; Schifano et al, 
2008). Scientific rigour has not been ignored in collecting and reporting these deaths; we have not 
attempted to shoe-horn individual cases into categories which support a particular view-point with 
regard to the status of khat. 
 
The Programme‟s objectives are primarily to inform the debate on substance use and misuse. This is 
done in a non-partisan, apolitical, and as objective a manner as possible. We let the facts speak for 
themselves. We do not hold any particular view about substance use – other than to reduce and 
prevent associated deaths. The Programme, like the INCB, merely brings information to the notice of 
policy-makers and leaves them to make their own judgements. If commentators wish to see our 
research as politically motivated – that is up to them. They should also be open about their own 
perspectives and views; there is no embarrassment in stating what one‟s stance is and why it is held.  
 
np-SAD believes there are potentially serious consequences that can result from the use of khat. 
These need to be aired, especially when there are constituencies that may wish to avoid mentioning 
such eventualities, as that serves their purposes more than those who might suffer as a consequence 
of lack of information – or indeed misinformation. These issues need to be heard and discussed in an 
informed way. As Klein has co-written in a Briefing just published by the EMCDDA (2011) “khat 
research is in its infancy and there is little robust information on the subject”.    
 
The need to place khat-related deaths in context is rightly pointed out by Singleton in her 
commentary, and her piece helps to do that. Our paper does not seek to overstate the risk of mortality 
from khat but highlight the potential for death by reference to actual specific instances, rather than 
ignoring the sad loss of lives from what is often put forward by some constituencies as benign and 
harmless. 
 
This is also true of former „legal highs‟ such as mephedrone. The media interest in alleged fatalities in 
the UK due its use was often „over the top‟, but may have helped in preventing some deaths. In the 
event, np-SAD is currently aware of at least 110 alleged deaths, of which about 80 have been 
confirmed by toxicological investigation as having consumed mephedrone prior to death. To date, 
legal inquiries (inquests, etc) have been completed for nearly 50 of these cases; in half of these, 
mephedrone was implicated in death; it was given as sole cause of death in 8 cases, suggesting the 
acute toxicity potential of the substance. 
 
With regard to khat, mephedrone or other novel psychoactive chemicals that emerge as recreational 
substances, np-SAD does not seek to label such substances as „killers‟, but to put on record 
instances of fatalities where (a) these drugs have been found, providing evidence of their use and  
epidemiology, and (b) where they have caused or contributed to death. This helps in providing pieces 
of the jigsaw so that policy-makers can decide what the picture on the lid might look like. 
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